Study duration per participant will be approximately 16 weeks and up to 29 weeks including up to 5 weeks screening period, a 12-week treatment period and up to 12 weeks post-treatment follow-up period or until the participant switches to commercialized dupilumab (or other biologic product), whichever comes first.
Primary Objective:~To assess the effect of dupilumab on sleep~Secondary Objectives:~To evaluate the effect of dupilumab on additional patient reported sleep outcomes~To evaluate the effect of dupilumab on objective sleep assessment~To evaluate the effect of dupilumab on asthma symptoms~To evaluate the effect of dupilumab on lung function~To evaluate the safety of dupilumab